Precisely translating computed tomography diagnosis accuracy into therapeutic intervention by a carbon-iodine conjugated polymer

Mingming Yin, Xiaoming Liu, Ziqiao Lei, Yuting Gao, Jia‐Cheng Liu, Sidan Tian, Zhiwen Liang, Ye Wang, Fanling Meng, Liang Luo

Abstract

The advancement of precision medicine necessitates the development of multifunctional markers that can seamlessly bridge the gap between diagnostic imaging and therapeutic procedures. Current X-ray computed tomography (CT) contrast agents often fall short due to rapid clearance, lack of visual cues for surgeons, or the generation of imaging artifacts. This study introduces poly(diiododiacetylene) (PIDA), a conjugated polymer composed entirely of carbon and iodine, as an ultraefficient CT contrast agent. With a record-high iodine payload (>84 wt%) and a deep blue color for dual visibility, PIDA enables precise CT-guided preoperative planning and visualization-guided surgery. Furthermore, PIDA excels as a fiducial marker for robotic radiotherapy, demonstrating superior biocompatibility and zero streak artifacts compared to traditional metal markers.

The Challenge: The "Translation Gap"

In clinical oncology, a persistent "translation gap" exists between identifying a tumor on a scan and accurately treating it in the operating room or radiation suite. Standard small-molecule contrast agents, such as iohexol, are cleared by the body within minutes, rendering them ineffective for guiding long surgeries or multi-day radiation treatments.

Moreover, permanent fiducial markers used to track tumors during radiotherapy—typically made of gold—often cause "streak artifacts" on CT scans. These artifacts obscure surrounding tissue and can lead to inaccurate radiation dosing. Finally, most CT agents are invisible to the human eye, meaning surgeons cannot easily see the "marked" area during a physical procedure, relying instead on indirect guidance.

The PIDA Solution

Researchers synthesized PIDA using a topochemical polymerization strategy. By employing a specific oxalamide scaffold to align diiodobutadiyne monomers, they created a stable conjugated polymer that can be formulated into injectable nanofibers (30–50 nm in diameter).

Key Innovations:

  • Record-High Iodine Payload: PIDA contains 84.1 wt% iodine, significantly higher than the ~46% found in clinical agents like iohexol.
  • Aggregation-Induced Amplification: A striking feature of PIDA is that when the nanofibers aggregate at an injection site, the CT signal intensity increases by over 10-fold. This "signal boost" allows for high-contrast marking using very low doses of iodine.
  • Dual-Visibility: Because PIDA is a highly conjugated polymer, it is naturally deep blue. This enables "visualization-guided surgery," where the same marker seen on a preoperative CT scan is physically visible to the surgeon’s eye, eliminating guesswork regarding tumor margins.

Experimental Results and Validation

The performance of PIDA was validated through several rigorous animal and phantom models:

  • Surgical Guidance: In orthotopic xenograft rat models, PIDA’s blue color provided clear visual boundaries for tumor resection, matching the high-contrast signals seen on preoperative CT scans.
  • Radiotherapy Precision: In Beagle dog models, PIDA markers allowed a robotic Stereotactic Body Radiation Therapy (SBRT) system to track lung and liver movement with a correlation error of only 1.07 mm, well within clinical safety thresholds.
  • Artifact-Free Imaging: In thorax phantom studies, PIDA showed negligible interference with surrounding tissue visibility. Unlike gold markers, which cause significant signal distortion, PIDA allowed for highly accurate radiation dose calculations.
  • Retention and Biocompatibility: While clinical iohexol signals decayed within one hour, PIDA maintained high CT values (>500 HU) for over six hours and remained detectable for days. Unlike permanent metal markers, PIDA is gradually biodegradable via reactive oxygen species (ROS) and carbon-iodine bond cleavage.

Conclusion and Future Outlook

PIDA represents a significant leap forward in bridging the gap between diagnosis and therapy. By providing high-contrast, artifact-free imaging alongside direct visual guidance, it offers a more precise and safer alternative to current clinical standards. While initial results in rat and dog models are highly promising, future research will focus on human clinical trials and the potential for functionalizing PIDA nanofibers for systemic targeting of metastatic tumors.

Summary updated

Abstract

X-ray computed tomography (CT) has an important role in precision medicine. However, CT contrast agents with high efficiency and the ability to translate diagnostic accuracy into therapeutic intervention are scarce. Here, poly(diiododiacetylene) (PIDA), a conjugated polymer composed of only carbon and iodine atoms, is reported as an efficient CT contrast agent to bridge CT diagnostic imaging with therapeutic intervention. PIDA has a high iodine payload (>84 wt%), and the aggregation of nanofibrous PIDA can further amplify CT intensity and has improved geometrical and positional stability in vivo. Moreover, with a conjugated backbone, PIDA is in deep blue color, making it dually visible by both CT imaging and the naked eyes. The performance of PIDA in CT-guided preoperative planning and visualization-guided surgery is validated using orthotopic xenograft rat models. In addition, PIDA excels clinical fiducial markers of imaging-guided radiotherapy in efficiency and biocompatibility, and exhibits successful guidance of robotic radiotherapy on Beagles, demonstrating clinical potential to translate CT diagnosis accuracy into therapeutic intervention for precision medicine.
BibTeX
@inproceedings{yin2022precisely,
  author = {Mingming Yin and Xiaoming Liu and Ziqiao Lei and Yuting Gao and Jia‐Cheng Liu and Sidan Tian and Zhiwen Liang and Ye Wang and Fanling Meng and Liang Luo},
  title = {{Precisely translating computed tomography diagnosis accuracy into therapeutic intervention by a carbon-iodine conjugated polymer}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-30263-1},
}
Figure